BioMarin Pharmaceutical Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
BioMarin Pharmaceutical heeft een totaal eigen vermogen van $5.4B en een totale schuld van $594.6M, wat de schuld-eigenvermogensverhouding op 11% brengt. De totale activa en totale passiva bedragen respectievelijk $6.9B en $1.4B. De EBIT BioMarin Pharmaceutical is $326.4M waardoor de rentedekking -5.5 is. Het heeft contanten en kortetermijnbeleggingen van $930.4M.
Belangrijke informatie
11.0%
Verhouding schuld/eigen vermogen
US$594.63m
Schuld
| Rente dekkingsratio | -5.5x |
| Contant | US$930.44m |
| Aandelen | US$5.41b |
| Totaal verplichtingen | US$1.44b |
| Totaal activa | US$6.85b |
Recente financiële gezondheidsupdates
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27Recent updates
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $3.1B ) BMRN } overtreffen de korte termijn passiva ( $715.7M ).
Langlopende schulden: De kortetermijnactiva BMRN ( $3.1B ) overtreffen de langetermijnschulden ( $722.1M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: BMRN heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van BMRN is de afgelopen 5 jaar gedaald van 27.4% naar 11%.
Schuldendekking: De schuld van BMRN wordt goed gedekt door de operationele kasstroom ( 69.7% ).
Rentedekking: BMRN verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.